Indonesia vs Mus: The number of people with susceptibility test result for rifampicin
Indonesia
144,511
in 2021
Mus
83
in 2021
Indonesia rank
3rd
Mus rank
1st
The number of people with susceptibility test result for rifampicin over time
- Indonesia
- Mus
How they compare
Indonesia currently reports 144,511 against 83 in Mus, a difference of 144,428.
That makes Indonesia's figure about 1,741.1 times Mus's.
Across all 5 years both countries report, Indonesia has been ahead every year.
Indonesia ranks 3rd and Mus ranks 1st of 155 countries.
Indonesia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Indonesia | Mus | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 71,327 | 111 | 71,216 | Indonesia |
| 2020s | 121,178 | 83 | 121,096 | Indonesia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Indonesia or Mus?
- Indonesia, at 144,511 against 83 in Mus as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Indonesia and Mus?
- 144,428, with Indonesia ahead.
- How many years of comparable data are there for Indonesia and Mus?
- 5 years are reported by both, from 2017 to 2021.
- How do Indonesia and Mus rank globally for the number of people with susceptibility test result for rifampicin?
- Indonesia ranks 3rd and Mus ranks 1st of 155 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid refreshes it automatically from the source and publishes the full history for both places.